Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). din il-preparazzjoni ma fihiex il-fattur von willebrand u għalhekk mhux indikat fil-von willebrand-marda tal -.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplażmi kolorettali - antineoplastic agents, protein kinase inhibitors - stivarga huwa indikat bħala monoterapija għall-kura ta ' pazjenti adulti bil:kanċer metastatiku tal-kolorektum (crc) li kienu kkurati minn qabel b', jew mhumiex ikkunsidrati li huma kandidati għall, disponibbli terapiji - dawn jinkludu kimoterapija bbażata fuq fluoropyrimidine, kontra l-vegf-terapija u anti-egfr-terapija;li ma jistgħax jitneħħa kirurġikament, jew li mmetastatizza tumuri stromali gastro-intestinali (gist) li mexa fuq jew li huma intolleranti għal qabel għal trattament b'imatinib u sunitinib;karċinoma epatoċellulari (hcc) li kienu kkurati minn qabel b'sorafenib.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - telmisartan - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - hypertensiontreatment ta'l-ipertensjoni essenzjali fl-adulti. kardjovaskulari preventionreduction tal-morbidità kardjovaskulari f'pazjenti bi: - manifest aterotrombotiċi mard kardjovaskulari (passat ta ' mard koronarju tal-qalb, puplesija, jew mard arterjali periferali) jew;dijabete tat-tip 2 mellitus dokumentata-mira-ħsara fl-organi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer animal health gmbh  - pradofloxacin - antibatteriċi għal użu sistemiku, fluoroquinolones - dogs; cats - dogstreatment ta':infezzjonijiet ta 'ġrieħi kkawżati minn strejns suxxetibbli ta' l-staphylococcus intermedius-grupp (inkluż i. pseudintermedius);superfiċjali u l-fond pijoderma ikkawżata minn strejns suxxetibbli ta ' l-staphylococcus intermedius-grupp (inkluż i. pseudintermedius);akuta urinarja-passaġġ infezzjonijiet ikkawżati minn razez suxxettibbli ta ' eschericia coli u staphylococcus intermedius-grupp (inkluż i. pseudintermedius);bħala trattament aġġuntiv għall-mekkaniċi jew kirurġiċi perjodontali-terapija fit-trattament ta 'infezzjonijiet severi tal-gingiva u perjodontali-tessuti ikkawżata minn strejns suxxetibbli ta' l-organiżmi anaerobiċi, per eżempju porphyromonas spp. u prevotella spp. catstreatment ta 'infezzjonijiet akuti tal-passaġġ respiratorju ta'fuq ikkawżata minn strejns suxxetibbli ta' pasteurella multocida, escherichia coli u staphylococcus intermedius-grupp (inkluż i. pseudintermedius).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - darolutamide - prostatika neoplażmi, il-kastrazzjoni-reżistenti - terapija endokrinali - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - riociguat - pressjoni għolja, pulmonari - antihypertensives għall-ipertensjoni arterjali pulmonari - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. l-effikaċja ġiet murija fil-pah popolazzjoni inklużi l-etjoloġiji ta idjopatika jew li tintiret-pah jew pah assoċċjata ma'mard tal-connective tissue. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag  - vardenafil - disfunzjoni erettili - uroloġiċi - trattament ta 'disfunzjoni erettili f'irġiel adulti. id-disfunzjoni erettili hija l-inkapaċità li tinkiseb jew tinżamm erezzjoni tal-pene suffiċjenti għal prestazzjoni sesswali sodisfaċenti. biex levitra ikun effettiv, hija meħtieġa stimulazzjoni sesswali. levitra mhux indikat għall-użu min-nisa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - sorafenib - carcinoma, hepatocellular; carcinoma, renal cell - aġenti antineoplastiċi - epatoċellulari carcinomanexavar huwa indikat għall-kura ta ' karċinoma epatoċellulari. taċ-ċelluli renali carcinomanexavar huwa indikat għall-kura ta ' pazjenti b'karċinoma taċ-ċellola renali li kellhom falliment ta qabel l-interferon-alpha jew interleukin-2 ibbażat fuq it-terapija jew li huma ikkunsidrati mhux tajba għal terapija bħal din. tat-tirojde differenzjat carcinomanexavar huwa indikat għall-kura ta ' pazjenti b'progressiva, lokalment avvanzat jew dak metastatiku, differenzjati (papillari/follikulari/hürthle taċ-ċelluli) karċinoma tat-tirojde, refrattarji għat-jodju radjuattiv.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - aġenti antitrombotiċi - xarelto, mogħti flimkien ma 'acetylsalicylic acid (asa) waħdu jew ma' asa flimkien ma ' clopidogrel jew ticlopidine, huwa indikat għall-prevenzjoni ta'avvenimenti aterotrombotiċi f'pazjenti adulti wara l-sindromu koronarju akut (acs) mal-bijomarkaturi kardijaċi għoljin. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevenzjoni ta ' l-thromboembolism venous (vte) fil-pazjenti adulti li għaddejjin minn elettiva għadma jew irkoppa sostituzzjoni kirurġija. trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, kombinazzjonijiet - majjali (ħnienes) - għall-konkorrenti-prevenzjoni ta 'sinjali kliniċi tal-koċċidjożi (bħal dijarea) fit-trabi tat-twelid qżieqeż fuq l-irziezet kkonfermati b'-istorja tal-koċċidjożi kkawżati minn cystoisospora suis, u l-prevenzjoni ta 'defiċjenza ta' ħadid anemija.